Advertisement

Risk of Parkinson’s disease after colectomy: longitudinal follow-up study using a national sample cohort

  • Young-Ju Kim
  • Chang-Min Lee
  • Seongheon Kim
  • Jae-Won Jang
  • Seo-Young Lee
  • Seung-Hwan LeeEmail author
Original Communication

Abstract

Background and purpose

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by deposition of intraneural inclusion bodies in the brain as well as the enteric nervous system. Emerging concepts regarding the brain–gut axis have been proposed for neurological disorders. Thus, the present study investigated the associations between colectomy and developing PD.

Methods

We conducted a retrospective cohort study using National Health Insurance Service–National Sample Cohort of Korea. This study included patients who underwent colectomy during 2003–2009, and up to 10 individuals per patient, matched in terms of age and sex, who did not undergo colectomy. The colectomy group was subdivided by the causes and surgical methods of colectomy. The risk of PD occurrence was evaluated over a follow-up period of at least 6 years using Cox regression analyses.

Results

Colectomy was associated with a higher risk of developing PD (adjusted hazard ratio [HR]: 1.962; 95% confidence interval [CI] 1.002–3.840). There was no significant difference in the occurrence of PD among the subgroups classified by the causes or surgical methods of colectomy.

Conclusions

Colectomy was associated with the development of PD, suggesting that colon issues play an important role in the pathophysiological mechanisms of PD.

Keywords

Parkinson’s disease Colectomy National sample cohort Risk factor 

Notes

Author contributions

Conceptualization: Y-JK, S-YL, and S-HL. Data curation: Y-JK, C-ML, and S-HL. Formal analysis: Y-JK, C-ML, and S-HL. Investigation: Y-JK, C-ML, S-YL, and S-HL. Methodology: Y-JK, SK, J-WJ, and S-HL. Project administration: Y-JK and S-HL. Resources: Y-JK and S-HL. Software: Y-JK and C-ML. Supervision: Y-JK and S-HL. Validation: SK, J-WJ, S-YL, and S-HL. Writing: original draft: Y-JK, C-ML, and S-HL. Writing, review and editing: Y-JK, SK, J-WJ, S-YL, and S-HL.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the Institutional Review Board of Kangwon National University Hospital (KNUH-2018-06-004).

References

  1. 1.
    Sakakibara R, Hattori T, Uchiyama T et al (2000) Micturitional disturbance in pure autonomic failure. Neurology 54:499–501CrossRefGoogle Scholar
  2. 2.
    Brown TP, Rumsby PC, Capleton AC et al (2006) Pesticides and Parkinson’s disease—is there a link? Environ Health Perspect 114:156–164CrossRefGoogle Scholar
  3. 3.
    Gupta A, Dawson VL, Dawson TM (2008) What causes cell death in Parkinson’s disease? Ann Neurol 64(Suppl 2):S3–S15.  https://doi.org/10.1002/ana.21573 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909CrossRefGoogle Scholar
  5. 5.
    Braak H, Tredici KD, Rüb U et al (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211.  https://doi.org/10.1016/S0197-4580(02)00065-9 CrossRefPubMedGoogle Scholar
  6. 6.
    Palma J-A, Kaufmann H (2014) Autonomic disorders predicting Parkinson’s disease. Parkinsonism Relat Disord 20:S94–S98.  https://doi.org/10.1016/S1353-8020(13)70024-5 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cersosimo MG, Benarroch EE (2012) Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol Dis 46:559–564.  https://doi.org/10.1016/j.nbd.2011.10.014 CrossRefPubMedGoogle Scholar
  8. 8.
    Braak H, Rüb U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm Vienna Austria 1996 110:517–536.  https://doi.org/10.1007/s00702-002-0808-2 CrossRefGoogle Scholar
  9. 9.
    Olanow CW, Prusiner SB (2009) Is Parkinson’s disease a prion disorder? Proc Natl Acad Sci USA 106:12571–12572.  https://doi.org/10.1073/pnas.0906759106 CrossRefPubMedGoogle Scholar
  10. 10.
    Abbott RD, Petrovitch H, White LR et al (2001) Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 57:456–462CrossRefGoogle Scholar
  11. 11.
    Shannon KM, Keshavarzian A, Dodiya HB et al (2012) Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. Mov Disord 27:716–719.  https://doi.org/10.1002/mds.25020 CrossRefPubMedGoogle Scholar
  12. 12.
    Postuma RB, Gagnon J-F, Pelletier A, Montplaisir J (2013) Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies. Mov Disord 28:597–604.  https://doi.org/10.1002/mds.25445 CrossRefPubMedGoogle Scholar
  13. 13.
    Orimo S, Uchihara T, Nakamura A et al (2008) Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson’s disease. Brain J Neurol 131:642–650.  https://doi.org/10.1093/brain/awm302 CrossRefGoogle Scholar
  14. 14.
    Orimo S, Takahashi A, Uchihara T et al (2007) Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease. Brain Pathol Zurich Switz 17:24–30.  https://doi.org/10.1111/j.1750-3639.2006.00032.x CrossRefGoogle Scholar
  15. 15.
    Goldstein DS (2006) Orthostatic hypotension as an early finding in Parkinson’s disease. Clin Auton Res 16:46–54.  https://doi.org/10.1007/s10286-006-0317-8 CrossRefPubMedGoogle Scholar
  16. 16.
    Pfeiffer RF (2018) Gastrointestinal Dysfunction in Parkinson’s Disease. Curr Treat Options Neurol 20:54.  https://doi.org/10.1007/s11940-018-0539-9 CrossRefPubMedGoogle Scholar
  17. 17.
    Derkinderen P, Rouaud T, Lebouvier T et al (2011) Parkinson disease: the enteric nervous system spills its guts. Neurology 77:1761–1767.  https://doi.org/10.1212/WNL.0b013e318236ef60 CrossRefPubMedGoogle Scholar
  18. 18.
    Miki Y, Mori F, Wakabayashi K et al (2009) Incidental Lewy body disease restricted to the heart and stellate ganglia. Mov Disord 24:2299–2301.  https://doi.org/10.1002/mds.22775 CrossRefPubMedGoogle Scholar
  19. 19.
    Mulak A (2015) Brain–gut–microbiota axis in Parkinson’s disease. World J Gastroenterol 21:10609.  https://doi.org/10.3748/wjg.v21.i37.10609 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Parashar A, Udayabanu M (2017) Gut microbiota: implications in Parkinson’s disease. Parkinsonism Relat Disord 38:1–7.  https://doi.org/10.1016/j.parkreldis.2017.02.002 CrossRefPubMedGoogle Scholar
  21. 21.
    Sampson TR, Debelius JW, Thron T et al (2016) Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell 167:1469–1480.e12.  https://doi.org/10.1016/j.cell.2016.11.018 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Leal MC, Casabona JC, Puntel M, Pitossi FJ (2013) Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s disease? Front Cell Neurosci 7:53.  https://doi.org/10.3389/fncel.2013.00053 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mogi M, Harada M, Riederer P et al (1994) Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208–210.  https://doi.org/10.1016/0304-3940(94)90746-3 CrossRefPubMedGoogle Scholar
  24. 24.
    Hui KY, Fernandez-Hernandez H, Hu J et al (2018) Functional variants in the LRRK2 gene confer shared effects on risk for Crohn’s disease and Parkinson’s disease. Sci Transl Med.  https://doi.org/10.1126/scitranslmed.aai7795 CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    An SJ, Lee SH, Lee SY et al (2017) Femur fractures in Parkinsonism: analysis of a national sample cohort in South Korea. J Clin Neurol 13:380–386.  https://doi.org/10.3988/jcn.2017.13.4.380 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hanyuda A, Ogino S, Qian ZR et al (2016) Body mass index and risk of colorectal cancer according to tumor lymphocytic infiltrate. Int J Cancer 139:854–868.  https://doi.org/10.1002/ijc.30122 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ahmadi A, Mobasheri M, Hashemi-Nazari SS et al (2014) Prevalence of hypertension and type 2 diabetes mellitus in patients with colorectal cancer and their median survival time: a cohort study. J Res Med 19:850–854Google Scholar
  28. 28.
    Anuurad E, Shiwaku K, Nogi A et al (2003) The new BMI criteria for asians by the regional office for the western pacific region of WHO are suitable for screening of overweight to prevent metabolic syndrome in elder Japanese workers. J Occup Health 45:335–343CrossRefGoogle Scholar
  29. 29.
    Chen RC, Chang SF, Su CL et al (2001) Prevalence, incidence, and mortality of PD A door-to-door survey in Ilan County, Taiwan. Neurology 57:1679–1686CrossRefGoogle Scholar
  30. 30.
    Tan LCS, Venketasubramanian N, Hong CY et al (2004) Prevalence of Parkinson disease in Singapore: Chinese vs Malays vs Indians. Neurology 62:1999–2004CrossRefGoogle Scholar
  31. 31.
    Seo W-K, Koh S-B, Kim B-J et al (2007) Prevalence of Parkinson’s disease in Korea. J Clin Neurosci 14:1155–1157.  https://doi.org/10.1016/j.jocn.2006.09.005 CrossRefPubMedGoogle Scholar
  32. 32.
    Yamawaki M, Kusumi M, Kowa H, Nakashima K (2009) Changes in prevalence and incidence of Parkinson’s disease in Japan during a quarter of a century. Neuroepidemiology 32:263–269.  https://doi.org/10.1159/000201565 CrossRefPubMedGoogle Scholar
  33. 33.
    Schrag A, Horsfall L, Walters K et al (2015) Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol 14:57–64.  https://doi.org/10.1016/S1474-4422(14)70287-X CrossRefPubMedGoogle Scholar
  34. 34.
    Pont-Sunyer C, Hotter A, Gaig C et al (2015) The onset of nonmotor symptoms in Parkinson’s disease (the ONSET PD study). Mov Disord 30:229–237.  https://doi.org/10.1002/mds.26077 CrossRefPubMedGoogle Scholar
  35. 35.
    Abbott RD, Ross GW, Petrovitch H et al (2007) Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 22:1581–1586.  https://doi.org/10.1002/mds.21560 CrossRefPubMedGoogle Scholar
  36. 36.
    Savica R, Carlin JM, Grossardt BR et al (2009) Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73:1752–1758.  https://doi.org/10.1212/WNL.0b013e3181c34af5 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Gao X, Chen H, Schwarzschild MA, Ascherio A (2011) A prospective study of bowel movement frequency and risk of Parkinson’s disease. Am J Epidemiol 174:546–551.  https://doi.org/10.1093/aje/kwr119 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Lin C-H, Lin J-W, Liu Y-C et al (2014) Risk of Parkinson’s disease following severe constipation: a nationwide population-based cohort study. Parkinsonism Relat Disord 20:1371–1375.  https://doi.org/10.1016/j.parkreldis.2014.09.026 CrossRefPubMedGoogle Scholar
  39. 39.
    Cersosimo MG, Raina GB, Pecci C et al (2013) Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J Neurol 260:1332–1338.  https://doi.org/10.1007/s00415-012-6801-2 CrossRefPubMedGoogle Scholar
  40. 40.
    Fearnley JM, Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain J Neurol 114(Pt 5):2283–2301.  https://doi.org/10.1093/brain/114.5.2283 CrossRefGoogle Scholar
  41. 41.
    Morrish PK, Rakshi JS, Bailey DL et al (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64:314–319.  https://doi.org/10.1136/jnnp.64.3.314 CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Powers KM, Smith-Weller T, Franklin GM et al (2006) Diabetes, smoking, and other medical conditions in relation to Parkinson’s disease risk. Parkinsonism Relat Disord 12:185–189.  https://doi.org/10.1016/j.parkreldis.2005.09.004 CrossRefPubMedGoogle Scholar
  43. 43.
    Giulio Scigliano, Massimo Musicco, Paola Soliveri et al (2006) Reduced risk factors for vascular disorders in Parkinson disease patients. Stroke 37:1184–1188.  https://doi.org/10.1161/01.STR.0000217384.03237.9c CrossRefGoogle Scholar
  44. 44.
    Miyake Y, Tanaka K, Fukushima W et al (2010) Case–control study of risk of Parkinson’s disease in relation to hypertension, hypercholesterolemia, and diabetes in Japan. J Neurol Sci 293:82–86.  https://doi.org/10.1016/j.jns.2010.03.002 CrossRefPubMedGoogle Scholar
  45. 45.
    Guttman M, Slaughter PM, Theriault M-E et al (2004) Parkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort. Mov Disord 19:49–53.  https://doi.org/10.1002/mds.10648 CrossRefPubMedGoogle Scholar
  46. 46.
    Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM (2012) Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study. Arch Neurol 69:1572–1577.  https://doi.org/10.1001/archneurol.2012.2261 CrossRefPubMedGoogle Scholar
  47. 47.
    Peretz C, Gurel R, Rozani V et al (2016) Cancer incidence among Parkinson’s disease patients in a 10-years time-window around disease onset: a large-scale cohort study. Parkinsonism Relat Disord 28:68–72.  https://doi.org/10.1016/j.parkreldis.2016.04.028 CrossRefPubMedGoogle Scholar
  48. 48.
    Lin P-Y, Chang S-N, Hsiao T-H et al (2015) Association between parkinson disease and risk of cancer in Taiwan. JAMA Oncol 1:633–640.  https://doi.org/10.1001/jamaoncol.2015.1752 CrossRefPubMedGoogle Scholar
  49. 49.
    Wirdefeldt K, Weibull CE, Chen H et al (2014) Parkinson’s disease and cancer: a register-based family study. Am J Epidemiol 179:85–94.  https://doi.org/10.1093/aje/kwt232 CrossRefPubMedGoogle Scholar
  50. 50.
    Svensson E, Horváth-Puhó E, Thomsen RW et al (2015) Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol 78:522–529.  https://doi.org/10.1002/ana.24448 CrossRefPubMedGoogle Scholar
  51. 51.
    Liu B, Fang F, Pedersen NL et al (2017) Vagotomy and Parkinson disease: a Swedish register-based matched-cohort study. Neurology 88:1996–2002CrossRefGoogle Scholar
  52. 52.
    Svensson E, Horváth-Puhó E, Stokholm MG et al (2016) Appendectomy and risk of Parkinson’s disease: a nationwide cohort study with more than 10 years of follow-up. Mov Disord 31:1918–1922.  https://doi.org/10.1002/mds.26761 CrossRefPubMedGoogle Scholar
  53. 53.
    Gray MT, Munoz DG, Gray DA et al (2014) Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects. Mov Disord 29:991–998.  https://doi.org/10.1002/mds.25779 CrossRefPubMedGoogle Scholar
  54. 54.
    Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13:701–712.  https://doi.org/10.1038/nrn3346 CrossRefPubMedGoogle Scholar
  55. 55.
    Tillisch K, Labus J, Kilpatrick L et al (2013) Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 144:1394–1401.  https://doi.org/10.1053/j.gastro.2013.02.043 1394–1401.e1 CrossRefPubMedGoogle Scholar
  56. 56.
    Heijtz RD, Wang S, Anuar F et al (2011) Normal gut microbiota modulates brain development and behavior. Proc Natl Acad Sci 108:3047–3052.  https://doi.org/10.1073/pnas.1010529108 CrossRefGoogle Scholar
  57. 57.
    Bercik P, Denou E, Collins J et al (2011) The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 141:599–609.e3.  https://doi.org/10.1053/j.gastro.2011.04.052 CrossRefPubMedGoogle Scholar
  58. 58.
    Scheperjans F, Aho V, Pereira PAB et al (2015) Gut microbiota are related to Parkinson’s disease and clinical phenotype. Mov Disord 30:350–358.  https://doi.org/10.1002/mds.26069 CrossRefPubMedGoogle Scholar
  59. 59.
    Keshavarzian A, Green SJ, Engen PA et al (2015) Colonic bacterial composition in Parkinson’s disease. Mov Disord 30:1351–1360.  https://doi.org/10.1002/mds.26307 CrossRefPubMedGoogle Scholar
  60. 60.
    Gabrielli M, Bonazzi P, Scarpellini E et al (2011) Prevalence of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 26:889–892.  https://doi.org/10.1002/mds.23566 CrossRefPubMedGoogle Scholar
  61. 61.
    Rana SV, Bhardwaj SB (2008) Small intestinal bacterial overgrowth. Scand J Gastroenterol 43:1030–1037.  https://doi.org/10.1080/00365520801947074 CrossRefPubMedGoogle Scholar
  62. 62.
    Tan AH, Mahadeva S, Thalha AM et al (2014) Small intestinal bacterial overgrowth in Parkinson’s disease. Parkinsonism Relat Disord 20:535–540.  https://doi.org/10.1016/j.parkreldis.2014.02.019 CrossRefPubMedGoogle Scholar
  63. 63.
    Fasano A, Bove F, Gabrielli M et al (2013) The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov Disord 28:1241–1249.  https://doi.org/10.1002/mds.25522 CrossRefPubMedGoogle Scholar
  64. 64.
    Rao SSC, Tan G, Abdulla H et al (2018) Does colectomy predispose to small intestinal bacterial (SIBO) and fungal overgrowth (SIFO)? Clin Transl Gastroenterol 9:146.  https://doi.org/10.1038/s41424-018-0011-x CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    van Minnen LP, Nieuwenhuijs VB, de Bruijn MT et al (2006) Effects of subtotal colectomy on bacterial translocation during experimental acute pancreatitis. Pancreas 32:110–114CrossRefGoogle Scholar
  66. 66.
    Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 57:1497–1499CrossRefGoogle Scholar
  67. 67.
    Rajput AH, Rozdilsky B, Rajput A (1991) Accuracy of clinical diagnosis in parkinsonism—a prospective study. Can J Neurol Sci J Can Sci Neurol 18:275–278CrossRefGoogle Scholar
  68. 68.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184.  https://doi.org/10.1136/jnnp.55.3.181 CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861–870.  https://doi.org/10.1093/brain/awf080 CrossRefPubMedGoogle Scholar
  70. 70.
    Joutsa J, Gardberg M, Röyttä M, Kaasinen V (2014) Diagnostic accuracy of parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord 20:840–844.  https://doi.org/10.1016/j.parkreldis.2014.04.019 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of StatisticsKangwon National UniversityChuncheonKorea
  2. 2.Department of NeurologyKangwon National University School of MedicineChuncheonKorea

Personalised recommendations